Lymphoma Newswire (Page 3)

Lymphoma Newswire (Page 3)

Comprehensive Real-Time News Feed for Lymphoma. (Page 3)

Results 41 - 60 of 44,483 in Lymphoma

  1. Yankees president: This is our best farm system since dynastyRead the original story

    Tuesday | New York Post

    ... Pitt (8-4), which beat Clemson and Penn State, features junior running back James Conner, who overcame Hodgkin's lymphoma and a knee injury in the past year before becoming a 1,000-yard runner and an All-ACC pick. "He has affected so many people's ...

    Comment?

  2. Is This How Juno Therapeutics Gets Back on Track?Read the original story w/Photo

    Tuesday | The Motley Fool

    ... at the conference that JCAR017 is delivering intriguing efficacy in relapsed/refractory diffuse large B cell lymphoma (DLBCL). In 20 evaluable patients, the overall response rate to JCAR017 was 80%, and that included 12 patients who were complete ...

    Comment?

  3. Cancer drug could help women grow new eggs - having huge fertility implicationsRead the original story w/Photo

    Tuesday | Mirror.co.uk

    ... the capacity to create babies . All eight women, who had an age range of 16 to 29, had been treated for Hodgkin's lymphoma with a drug combination known as ABVD. There were far more of them than could be seen in ovarian tissue from women who ...

    Comment?

  4. Fremd tries to save alum's life with bone marrow driveRead the original story w/Photo

    Tuesday | Daily Herald

    Fremd High School will host a bone marrow drive next week in hopes of saving the life of one of its alumni. Aaron Lee, a 34-year-old Fremd alumnus who grew up in Inverness, is battling Stage IV non-Hodgkin lymphoma.

    Comment?

  5. Next-generation Biologics Market - Top Drivers and Forecast from TechnavioRead the original story w/Photo

    Tuesday | Customer Interaction Solutions

    ... monoclonal immunoglobulin G1 antibody, which acts against CD30 expressed in HL and systemic anaplastic large cell lymphoma." Advancements in biological sciences have shown a positive influence on the global next-generation biologics market. There ...

    Comment?

  6. Next-generation Biologics Market a " Top Drivers and Forecast from TechnavioRead the original story w/Photo

    Tuesday | Business Wire

    ... monoclonal immunoglobulin G1 antibody, which acts against CD30 expressed in HL and systemic anaplastic large cell lymphoma." Advancements in biological sciences have shown a positive influence on the global next-generation biologics market. There ...

    Comment?

  7. Kite Pharma's lead product candidate shows high response rate in...Read the original story w/Photo

    Tuesday | Seeking Alpha

    Results from a pivotal Phase 1/2 clinical trial, ZUMA-1 , assessing Kite Pharma's lead product candidate axicabtagene ciloleucel in patients with chemorefractory aggressive non-Hodgkin lymphoma showed over 3/4 of patients responded to treatment. The data were presented at the 58th American Society of Hematology annual meeting in San Diego.

    Comment?

  8. BeiGene Ltd. (BGNE) Receives "Buy" Rating from Maxim GroupRead the original story w/Photo

    Tuesday | Daily Political

    "Today, AbbVie presented a five-year analysis and follow-up data of its BTK inhibitor Imbruvica for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma at the American Society of Hematology's Annual Meeting and Exposition. Conclusion.

    Comment?

  9. Immunotherapy Study Involving Wilmot Makes Headlines at National MeetingRead the original story w/Photo

    Tuesday | University of Rochester

    ... that's experiencing resurgence in new clinical trials that harness a person's own immune system to fight cancer. Lymphoma patient Ed Foster of Elmira, N.Y., was the first person in upstate New York at Wilmot to receive a new, powerful form of ...

    Comment?

  10. BRIEF-Kite Pharma presents results of multi-center pivotal Zuma-1...Read the original story w/Photo

    Tuesday | Reuters

    ... results of multi-center pivotal ZUMA-1 trial of Axicabtagene Ciloleucel (KTE-C19) in aggressive non-hodgkin lymphoma as late-breaking abstract at annual meeting of American Society of Hematology * Intends to seek regulatory approval of Axicabtagene ...

    Comment?

  11. First multicenter trial; Car T-cell immunotherapy effective for lymphomaRead the original story w/Photo

    Tuesday | PhysOrg Weblog

    A late-breaking abstract being presented today during the 58th American Society of Hematology Annual Meeting and Exposition in San Diego demonstrates that chimeric antigen receptor T-cell therapy is a promising option for treating refractory non-Hodgkin lymphoma and practical to implement in a variety of real-world clinical settings. The study, which involved 22 institutions and tested a product called KTE-C19 , is the first multicenter trial of this cellular immunotherapy-based treatment approach for lymphoma.

    Comment?

  12. BRIEF-Calithera Biosciences reports CB-839 Phase I triple negative breast cancer combination dataRead the original story w/Photo

    Tuesday | Reuters

    ... resents results of multi-center pivotal ZUMA-1 trial of Axicabtagene Ciloleucel (KTE-C19) in aggressive non-hodgkin lymphoma as late-breaking abstract at annual meeting of American Society of Hematology

    Comment?

  13. Chemotherapy drug may trigger new egg production in womenRead the original story w/Photo

    Tuesday | Medical News Today

    ... drugs known as ABVD (adriamycin, bleomycin, vinblastine, and dacarbazine) that is used to treat Hodgkin's lymphoma (HL) - an uncommon cancer of the lymphatic system. The Edinburgh team wanted to investigate this further by examining the follicles in ...

    Comment?

  14. A case for Conner: Why Pitt's RB should have been a Heisman finalistRead the original story w/Photo

    Tuesday | The Pitt News

    ... effort to do or achieve something despite difficulties, failure or opposition." both a torn MCL and Hodgkin lymphoma since the start of last season. Not only did he successfully rehab the injury and beat cancer, he did so with a goal of returning ...

    Comment?

  15. Novartis AG Announces Zykadia First-Line Study Results Showing 16.6...Read the original story

    Monday | BioSpace

    Novartis AG Announces Zykadia First-Line Study Results Showing 16.6 Month Progression-Free Survival In Patients With ALK+ Advanced NSCLC Novartis today announced results from its Phase III open-label, randomized, active-controlled, multi-center ASCEND-4 study, which found that patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer treated with first-line Zykadia had a median progression-free survival of 16.6 months , compared to 8.1 months in patients treated with standard first-line chemotherapy with maintenance.

    Comment?

  16. Nordic Nanovector: Betalutin In Combination With Rituximab...Read the original story

    Monday | BioSpace

    Data presented at the ASH Annual Meeting Oslo, Norway, 6 December 2016 Nordic Nanovector ASA announces that it has presented a poster describing the synergistic therapeutic effect of BetalutinA in combination with rituximab in a preclinical model of non-Hodgkin lymphoma . The new data was presented at the 58th Annual American Society of Hematology meeting .

    Comment?

  17. Hutchison China MediTech (Chi-Med) Presents Pre-Clinical Data For...Read the original story

    Monday | BioSpace

    ... The abnormal activation of BCR signaling is closely related to transformation and development of B-cell lymphoma. In vitro in B-cell lymphoma cell lines with Syk/BCR dysregulation, HMPL-523 was found to block phosphorylation of B-cell linker protein ...

    Comment?

  18. Seattle Genetics And Bristol-Myers Squibb Highlight First Data From...Read the original story

    Monday | BioSpace

    Seattle Genetics, Inc. and Bristol-Myers Squibb Company today highlighted the first reported data from an ongoing phase 1/2 clinical trial evaluating ADCETRIS in combination with Opdivo in relapsed or refractory classical Hodgkin lymphoma at the 58th American Society of Hematology Annual Meeting and Exposition taking place in San Diego, California, December 3-6, 2016. The data reported from 42 patients, including 29 evaluable for response, were featured in an oral presentation and selected to be included in the 2017 Highlights of ASH post-meeting program.

    Comment?

  19. Seattle Genetics Highlights Long-Term Follow-Up Data From...Read the original story

    Monday | BioSpace

    Seattle Genetics, Inc. , a global biotechnology company, today highlighted long-term follow-up data evaluating ADCETRIS in T-cell lymphoma at the 58th American Society of Hematology Annual Meeting and Exposition taking place in San Diego, California, December 3-6, 2016. The data included a presentation featuring five-year overall survival from the ADCETRIS pivotal phase 2 clinical trial in relapsed or refractory systemic anaplastic large cell lymphoma .

    Comment?

  20. Verastem Presents Phase 2 DYNAMO Clinical Data At American Society of ...Read the original story

    Monday | BioSpace

    Results from the study were presented by Dr. Ian Flinn in an oral presentation, "DYNAMO: A phase 2 study demonstrating the clinical activity of duvelisib in patients with refractory indolent non-Hodgkin lymphoma." Ian Flinn, M.D., Ph.D., Director of the Blood Cancer Research Program at Sarah Cannon Research Institute and the principal investigator on the DYNAMO study, described the results demonstrating duvelisib's clinical activity in patients with double refractory iNHL, which included robust and durable responses, and a manageable safety profile.

    Comment?